We collected four external independent immune therapy cohorts (anti-PD-1/PD-L1/CTLA-4) and a clinical cohort of advanced HNSCC patients receiving immune therapy to evaluate the performance of DRGs in predicting immune therapy response. Here, CD274 is linked to head and neck squamous cell carcinoma.